Advertisement

Dissemination of Neisseria meningitidis.

23:52 EDT 19th May 2013 | BioPortfolio

Summary of "Dissemination of Neisseria meningitidis."

No Summary Available

Affiliation

Infectious Diseases Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.

Journal Details

This article was published in the following journal.

Name: The New England journal of medicine
ISSN: 1533-4406
Pages: 1573-5

Links

Medical and Biotech [MESH] Definitions

Neisseria Meningitidis, Serogroup W-135

Strains of Neisseria meningitidis found mostly in Africa.

Neisseria Meningitidis, Serogroup C

Strains of Neisseria meningitidis responsible for most sporadic cases in teenagers and almost all outbreaks of disease in this age group. These strains are less common in infants.

Neisseria Meningitidis, Serogroup B

Strains of Neisseria meningitidis which are the most common ones causing infections or disease in infants. Serogroup B strains are isolated most frequently in sporadic cases, and are less common in outbreaks and epidemics.

Neisseria Meningitidis, Serogroup Y

Strains of Neisseria meningitidis which, in the United States, causes disease in mostly adults and the elderly. Serogroup Y strains are associated with PNEUMONIA.

Neisseria Meningitidis, Serogroup A

Strains of Neisseria meningitidis responsible for most outbreaks of meningococcal disease in Western Europe and the United States in the first half of the 20th century. They continue to be a major cause of disease in Asia and Africa, and especially localized epidemics in Sub-Sahara Africa.

PubMed Articles [ 962 Associated PubMed Articles listed on BioPortfolio]

A comparison of meningococcal carriage by pregnancy status.

ABSTRACT: Neisseria meningitidis is the second leading cause of invasive meningitis. A prerequisite for infection is colonization of the nasopharynx, and asymptomatic carrier rates are widely reported...

Molecular discrimination between Neisseria meningitidis serogroups W-135 and Y based on the nucleotide recognition domain sequence of the capsule polymerases.

Pathogenic Neisseria meningitidis isolates in most cases express one of five capsular polysaccharide-defined serogroups, i.e. A, B, C, W-135, and Y. ...

Clones of Neisseria meningitidis strains in Mali.

OBJECTIVE: The purpose of our study was to identify strains of Neisseria meningitidis isolated from 2005 to 2007 in Mali. PATIENTS AND METHOD: We carried out a cross-sectional and descriptive study of...

(1)H, (13)C and (15)N assignment of the GNA1946 outer membrane lipoprotein from Neisseria meningitidis.

GNA1946 (Genome-derived Neisseria Antigen 1946) is a highly conserved exposed outer membrane lipoprotein from Neisseria meningitidis bacteria of 287 amino acid length (31 kDa). Although the structure...

Posttranslational Modification of Pili upon Cell Contact Triggers N. meningitidis Dissemination.

The Gram-negative bacterium Neisseria meningitidis asymptomatically colonizes the throat of 10 to 30% of the human population, but throat colonization can also act as the port of entry to the blood (s...

Clinical Trials [ 68 Associated Clinical Trials listed on BioPortfolio]

Can we Reduce the Number of Vaccine Injections for Children?

This open label randomised controlled study will evaluate the induction of immunity following varying schedules of vaccination with glyco-conjugate Neisseria meningitidis serogroup C (MenC...

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-Valent Pneumococcal Conjugate Vaccine.

Three dose primary vaccination of healthy infants between 6 to 16 weeks of age at the time of the first vaccination against Streptococcus pneumonia, Neisseria meningitidis and Haemophilus...

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Have to be Vaccinated MenBVac®

The main objective of the study is to estimate the proportion of children, born between the 06/04/2004 and the 17/004/2008, living around Neufchatel en Bray, vaccinated by MenBVac, with a...

Study to Evaluate GlaxoSmithKline (GSK) Biologicals’ MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers

The purpose of this booster vaccination study is to evaluate the persistence and immune memory induced by a three-dose primary vaccination course with GSK Biologicals’ MenC-TT (Neisseria...

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-Priming With GSK Vaccine 792014

The purpose of the study is to characterize the immunogenicity & safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months o...

Search BioPortfolio: